{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:43:41Z","timestamp":1791438221975,"version":"4.3.3"},"reference-count":143,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,7,3]]},"DOI":"10.18632\/oncotarget.25661","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T13:31:23Z","timestamp":1530624683000},"page":"29820-29841","source":"Crossref","is-referenced-by-count":133,"title":["Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer"],"prefix":"10.18632","volume":"9","author":[{"given":"Noomi","family":"Vainer","sequence":"first","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dehlendorff","sequence":"additional","affiliation":[{"name":"Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia S.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(10)60353-4","article-title":"Colorectal cancer","volume":"375","author":"Starling","year":"2010","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Pox","year":"2014","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Gores","year":"2014","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Bardeesy","year":"2014","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13000-016-0497-z","article-title":"Surgical and molecular pathology of pancreatic neoplasms","volume":"11","author":"Brosens","year":"2016","journal-title":"Diagn Pathol"},{"key":"7","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.3748\/wjg.v20.i38.13804","article-title":"Pathogenetic mechanisms in gastric cancer","volume":"20","author":"Hou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"8","doi-asserted-by":"crossref","first-page":"13842","DOI":"10.3748\/wjg.v20.i38.13842","article-title":"Gastric cancer: prevention, screening and early diagnosis","volume":"20","author":"Leja","year":"2014","journal-title":"World J Gastroenterol"},{"key":"9","first-page":"28","article-title":"Advances in the management of biliary tract cancers","volume":"11","author":"Goff","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14712\/23362936.2015.65","article-title":"Pancreatic cancer diagnostics and treatment - current state","volume":"116","author":"Ulrych","year":"2015","journal-title":"Prague Med Rep"},{"key":"11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ncpgasthep0881","article-title":"Mechanisms of disease: chronic inflammation and cancer in the pancreas\u2014a potential role for pancreatic stellate cells?","volume":"4","author":"Schmid","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1499-3872(14)60259-9","article-title":"Interleukin-6: a villain in the drama of pancreatic cancer development and progression","volume":"13","author":"Kalthoff","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/1471-2407-13-463","article-title":"RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients","volume":"13","author":"Chatterjee","year":"2013","journal-title":"BMC Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10552-014-0445-8","article-title":"C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis","volume":"25","author":"Xing","year":"2014","journal-title":"Cancer Causes Control"},{"key":"15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Jemal","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"16","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Matrisian","year":"2014","journal-title":"Cancer Res"},{"key":"17","unstructured":"www.cancer.gov. Cancer statistics. 2017."},{"key":"18","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ijc.23273","article-title":"Colorectal cancer screening: a comparison of 35 initiatives in 17 countries","volume":"122","author":"Atkin","year":"2008","journal-title":"Int J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0032-1306895","article-title":"The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer","volume":"44","author":"Garborg","year":"2012","journal-title":"Endoscopy"},{"key":"20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5858\/arpa.2014-0080-ED","article-title":"Biomarkers and oncology: the path forward to a learning health system","volume":"139","author":"Hayes","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12885-017-3310-9","article-title":"Circulating blood levels of IL-6, IFN-gamma, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study","volume":"17","author":"Maldonado-Bernal","year":"2017","journal-title":"BMC Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molonc.2014.10.004","article-title":"Biomarker validation and testing","volume":"9","author":"Hayes","year":"2015","journal-title":"Mol Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"13791","DOI":"10.3748\/wjg.v20.i38.13791","article-title":"Potential prognostic, diagnostic and therapeutic markers for human gastric cancer","volume":"20","author":"Lin","year":"2014","journal-title":"World J Gastroenterol"},{"key":"24","first-page":"1423","article-title":"Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients","volume":"46","author":"Szmitkowski","year":"2008","journal-title":"Clin Chem Lab Med"},{"key":"25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOG.0b013e328325a894","article-title":"Serum and bile biomarkers for cholangiocarcinoma","volume":"25","author":"Alvaro","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"26","doi-asserted-by":"crossref","first-page":"67059","DOI":"10.1371\/journal.pone.0067059","article-title":"Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer","volume":"8","author":"Wojdemann","year":"2013","journal-title":"PLoS One"},{"key":"27","first-page":"105","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal","volume":"3","author":"Chamberlain","year":"2012","journal-title":"J Gastrointest Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Grandis","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Klein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Zhang","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"32","doi-asserted-by":"crossref","first-page":"1093722","DOI":"10.1080\/2162402X.2015.1093722","article-title":"Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis","volume":"5","author":"Harris","year":"2016","journal-title":"Oncoimmunology"},{"key":"33","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/ijc.29939","article-title":"CD90(+) stromal cells are the major source of IL-6, which supports cancer stem-like cells and inflammation in colorectal cancer","volume":"138","author":"Pinchuk","year":"2016","journal-title":"Int J Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.smim.2014.01.002","article-title":"Interleukin-6 in inflammatory and malignant diseases of the pancreas","volume":"26","author":"Algul","year":"2014","journal-title":"Semin Immunol"},{"key":"35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2016.11.010","article-title":"IL-6 roles - molecular pathway and clinical implication in pancreatic cancer - a systemic review","volume":"181","author":"Burz","year":"2017","journal-title":"Immunol Lett"},{"key":"36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1158\/1541-7786.MCR-15-0147","article-title":"IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b","volume":"13","author":"Gooderham","year":"2015","journal-title":"Mol Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cas.13332","article-title":"Interleukin-6\/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy","volume":"108","author":"Taketomi","year":"2017","journal-title":"Cancer Sci"},{"key":"38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.smim.2014.01.007","article-title":"The IL-6 feed-forward loop: a driver of tumorigenesis","volume":"26","author":"Bromberg","year":"2014","journal-title":"Semin Immunol"},{"key":"39","first-page":"8026494","article-title":"IL-6 inhibition reduces STAT3 activation and enhances the antitumor effect of carboplatin","volume":"2016","author":"Zhong","year":"2016","journal-title":"Mediators Inflamm"},{"key":"40","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/0008-5472.CAN-12-0122","article-title":"Tumor microenvironment complexity: emerging roles in cancer therapy","volume":"72","author":"DeClerck","year":"2012","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Kroep","year":"2015","journal-title":"Ann Oncol"},{"key":"42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Coussens","year":"2015","journal-title":"Cancer Cell"},{"key":"43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12032-015-0553-7","article-title":"Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis","volume":"32","author":"Cui","year":"2015","journal-title":"Med Oncol"},{"key":"44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/107999001459150","article-title":"Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator","volume":"21","author":"Catalano","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-016-1108-9","article-title":"Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials","volume":"18","author":"Jacobs","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"46","first-page":"2979307","article-title":"The Diagnostic Roles of Cytokines in Hepatobiliary Cancers","volume":"2017","author":"Barut","year":"2017","journal-title":"Biomed Res Int"},{"key":"47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2011.10.014","article-title":"Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"48","author":"Hudes","year":"2012","journal-title":"Eur J Cancer"},{"key":"48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/bjc.2013.174","article-title":"Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer","volume":"108","author":"Ochiai","year":"2013","journal-title":"Br J Cancer"},{"key":"49","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1535-7163.MCT-16-0899","article-title":"IL-6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma","volume":"16","author":"Beatty","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"50","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjc.2014.90","article-title":"Cancer and systemic inflammation: treat the tumour and treat the host","volume":"110","author":"McMillan","year":"2014","journal-title":"Br J Cancer"},{"key":"51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.it.2015.06.007","article-title":"Chronic inflammation and the development of malignancy in the GI tract","volume":"36","author":"Strober","year":"2015","journal-title":"Trends Immunol"},{"key":"53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2009.01.001","article-title":"IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer","volume":"15","author":"Karin","year":"2009","journal-title":"Cancer Cell"},{"key":"54","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Franceschi","year":"2016","journal-title":"Lancet Glob Health"},{"key":"55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbrc.2017.01.110","article-title":"TNF-alpha-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6\/STAT3 signaling pathway","volume":"484","author":"Zhang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5009\/gnl16265","article-title":"Expression of MicroRNA in Host Cells Infected with Helicobacter pylori","volume":"11","author":"Kim","year":"2017","journal-title":"Gut Liver"},{"key":"57","first-page":"6184","article-title":"CDX2 is involved in microRNA-associated inflammatory carcinogenesis in gastric cancer","volume":"14","author":"Takenoshita","year":"2017","journal-title":"Oncol Lett"},{"key":"58","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdr384","article-title":"Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project","volume":"23","author":"Sacerdote","year":"2012","journal-title":"Ann Oncol"},{"key":"59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/hel.12254","article-title":"Pathogenesis of gastric cancer","volume":"20","author":"Machado","year":"2015","journal-title":"Helicobacter"},{"key":"60","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1053\/j.gastro.2005.03.010","article-title":"Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells","volume":"128","author":"Gores","year":"2005","journal-title":"Gastroenterology"},{"key":"61","first-page":"195","article-title":"Cholangiocarcinoma: risk factors, environmental influences and oncogenesis","volume":"43","author":"Sergi","year":"2013","journal-title":"Ann Clin Lab Sci"},{"key":"62","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.510300522","article-title":"Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line","volume":"30","author":"Patel","year":"1999","journal-title":"Hepatology"},{"key":"63","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ijc.29445","article-title":"Inhibition of IL-6 signaling significantly reduces primary tumor growth and recurrencies in orthotopic xenograft models of pancreatic cancer","volume":"137","author":"Rose-John","year":"2015","journal-title":"Int J Cancer"},{"key":"64","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and colon cancer","volume":"138","author":"Karin","year":"2010","journal-title":"Gastroenterology"},{"key":"65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cam4.602","article-title":"Pretreatment serum interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha levels predict the progression of colorectal cancer","volume":"5","author":"Yeh","year":"2016","journal-title":"Cancer Med"},{"key":"66","first-page":"709","article-title":"Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma","volume":"25","author":"Chayama","year":"2005","journal-title":"Anticancer Res"},{"key":"67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10120-009-0509-8","article-title":"Serum interleukin-6 and -10 levels in patients with gastric cancer","volume":"12","author":"Tatebe","year":"2009","journal-title":"Gastric Cancer"},{"key":"68","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1349-7006.1997.tb00314.x","article-title":"Expression of interleukin-6 and its effect on the cell growth of gastric carcinoma cell lines","volume":"88","author":"Tahara","year":"1997","journal-title":"Jpn J Cancer Res"},{"key":"69","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1078-0432.CCR-07-1032","article-title":"Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"70","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10120-005-0315-x","article-title":"Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor","volume":"8","author":"Aoki","year":"2005","journal-title":"Gastric Cancer"},{"key":"71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2559.1998.00445.x","article-title":"Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma","volume":"33","author":"Nakanuma","year":"1998","journal-title":"Histopathology"},{"key":"72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000658-199803000-00012","article-title":"Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker","volume":"227","author":"Carty","year":"1998","journal-title":"Ann Surg"},{"key":"73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-016-0301-7","article-title":"Transcriptional repression of SOCS3 mediated by IL-6\/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis","volume":"35","author":"Wang","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"74","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1097\/MD.0000000000005926","article-title":"Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern","volume":"96","author":"Hwang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"75","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Ostrowski","year":"2018","journal-title":"Gut"},{"key":"76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00384-009-0818-8","article-title":"Serum interleukin - 6 levels in colorectal cancer patients - a summary of published results","volume":"25","author":"Preiss","year":"2010","journal-title":"Int J Colorectal Dis"},{"key":"77","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1158\/1078-0432.CCR-15-2422","article-title":"Prognostic impact of IL6 genetic variants in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy","volume":"22","author":"Loupakis","year":"2016","journal-title":"Clin Cancer Res"},{"key":"78","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3892\/ijo.2015.2851","article-title":"The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells","volume":"46","author":"Kawai","year":"2015","journal-title":"Int J Oncol"},{"key":"79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2407-9-155","article-title":"Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer","volume":"9","author":"Kim","year":"2009","journal-title":"BMC Cancer"},{"key":"80","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1572-0241.2007.01403.x","article-title":"Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy","volume":"102","author":"Shim","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"81","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1111\/j.1572-0241.2007.01394.x","article-title":"Targeting IL-6 in cholangiocarcinoma therapy","volume":"102","author":"Gores","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/jcla.20395","article-title":"Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis","volume":"24","author":"Szmitkowski","year":"2010","journal-title":"J Clin Lab Anal"},{"key":"83","doi-asserted-by":"crossref","first-page":"e2502","DOI":"10.1097\/MD.0000000000002502","article-title":"Diagnostic and prognostic value of serum interleukin-6 in colorectal cancer","volume":"95","author":"Wu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"84","first-page":"2235","article-title":"High interleukin-6 mRNA expression is a predictor of relapse in colon cancer","volume":"35","author":"Troelsen","year":"2015","journal-title":"Anticancer Res"},{"key":"85","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1159\/000350836","article-title":"In patients with colorectal cancer, preoperative serum interleukin-6 level and granulocyte\/lymphocyte ratio are clinically relevant biomarkers of long-term cancer progression","volume":"84","author":"Tabuchi","year":"2013","journal-title":"Oncology"},{"key":"86","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/bjc.2012.456","article-title":"Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma","volume":"107","author":"Makinen","year":"2012","journal-title":"Br J Cancer"},{"key":"87","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jss.2012.08.051","article-title":"Prognostic value of circulating cytokines for stage III colon cancer","volume":"182","author":"Nam","year":"2013","journal-title":"J Surg Res"},{"key":"88","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/1319-3767.80378","article-title":"Clinical relevance of serum vascular endothelial growth factor and interleukin-6 in patients with colorectal cancer","volume":"17","author":"Elhawary","year":"2011","journal-title":"Saudi J Gastroenterol"},{"key":"89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2407-10-203","article-title":"Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer"},{"key":"90","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jjco\/hyq010","article-title":"Analysis of the effect of serum interleukin-6 (IL-6) and soluble IL-6 receptor levels on survival of patients with colorectal cancer","volume":"40","author":"Liao","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"91","first-page":"3905","article-title":"Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma","volume":"26","author":"Hsu","year":"2006","journal-title":"Anticancer Res"},{"key":"92","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.thromres.2006.11.002","article-title":"Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer","volume":"120","author":"Kemona","year":"2007","journal-title":"Thromb Res"},{"key":"93","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2005.12.003","article-title":"Interleukin-6 level in patients with colorectal cancer","volume":"244","author":"Basati","year":"2006","journal-title":"Cancer Lett"},{"key":"94","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3748\/wjg.v11.i11.1639","article-title":"Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications","volume":"11","author":"Peros","year":"2005","journal-title":"World J Gastroenterol"},{"key":"95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.10269","article-title":"Serum interleukin-6 levels reflect the disease status of colorectal cancer","volume":"83","author":"Chang","year":"2003","journal-title":"J Surg Oncol"},{"key":"96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10434-000-0133-7","article-title":"Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer","volume":"7","author":"Jessup","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"97","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2526::AID-CNCR6>3.0.CO;2-3","article-title":"Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma","volume":"85","author":"Miki","year":"1999","journal-title":"Cancer"},{"key":"98","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF02361238","article-title":"Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis","volume":"29","author":"Urakawa","year":"1994","journal-title":"J Gastroenterol"},{"key":"99","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3748\/wjg.v23.i10.1780","article-title":"Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer","volume":"23","author":"Guo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"100","first-page":"23","article-title":"IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits","volume":"21","author":"Diaconu","year":"2012","journal-title":"J Gastrointestin Liver Dis"},{"key":"101","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3892\/etm.2011.424","article-title":"Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis","volume":"3","author":"Kinoshita","year":"2012","journal-title":"Exp Ther Med"},{"key":"102","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s00262-005-0047-0","article-title":"Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival","volume":"55","author":"Emanuelli","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"103","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1158\/1078-0432.CCR-13-0926","article-title":"Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)","volume":"19","author":"Hurwitz","year":"2013","journal-title":"Clin Cancer Res"},{"key":"104","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/hpb.12002","article-title":"Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil","volume":"15","author":"Dennison","year":"2013","journal-title":"HPB (Oxford)"},{"key":"105","doi-asserted-by":"crossref","first-page":"11168","DOI":"10.3748\/wjg.v21.i39.11168","article-title":"Prognostic significance of plasma interleukin-6\/-8 in pancreatic cancer patients receiving chemoimmunotherapy","volume":"21","author":"Okamoto","year":"2015","journal-title":"World J Gastroenterol"},{"key":"106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/etm.2012.553","article-title":"Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome","volume":"4","author":"Bellone","year":"2012","journal-title":"Exp Ther Med"},{"key":"107","doi-asserted-by":"publisher","first-page":"75013","DOI":"10.18632\/oncotarget.12601","article-title":"Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer","volume":"7","author":"Guren","year":"2016","journal-title":"Oncotarget"},{"key":"108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cam4.71","article-title":"Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab","volume":"2","author":"Nixon","year":"2013","journal-title":"Cancer Med"},{"key":"109","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00595-016-1404-7","article-title":"High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab","volume":"47","author":"Takeyama","year":"2017","journal-title":"Surg Today"},{"key":"110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP Working Group","volume":"11","author":"Berg","year":"2009","journal-title":"Genet Med"},{"key":"111","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1200\/JCO.2012.42.6858","article-title":"Publication of tumor marker research results: the necessity for complete and transparent reporting","volume":"30","author":"Hayes","year":"2012","journal-title":"J Clin Oncol"},{"key":"112","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1741-7015-10-51","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"10","author":"Taube","year":"2012","journal-title":"BMC Med"},{"key":"113","doi-asserted-by":"crossref","first-page":"e102436","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Takahashi","year":"2014","journal-title":"PLoS One"},{"key":"114","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-013-2488-z","article-title":"The role of intratumoral and systemic IL-6 in breast cancer","volume":"138","author":"Hojman","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"115","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s13277-015-3914-0","article-title":"The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease","volume":"37","author":"Kowalska","year":"2016","journal-title":"Tumour Biol"},{"key":"116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Lee","year":"2013","journal-title":"Mol Cancer"},{"key":"117","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3892\/or.2015.3838","article-title":"Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma","volume":"33","author":"Moriyama","year":"2015","journal-title":"Oncol Rep"},{"key":"118","first-page":"2761","article-title":"Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma","volume":"25","author":"Hormann","year":"2005","journal-title":"Anticancer Res"},{"key":"119","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00109-013-1080-7","article-title":"The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications\u2014a review","volume":"91","author":"Madeddu","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.mce.2011.05.033","article-title":"Interleukin-6: a multifunctional targetable cytokine in human prostate cancer","volume":"360","author":"Puhr","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"121","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2005.05.155","article-title":"Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma","volume":"23","author":"Gunduz","year":"2005","journal-title":"J Clin Oncol"},{"key":"122","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jjco\/28.1.12","article-title":"Elevated serum interleukin-6 levels in patients with pancreatic cancer","volume":"28","author":"Kakizoe","year":"1998","journal-title":"Jpn J Clin Oncol"},{"key":"123","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3748\/wjg.v10.i8.1115","article-title":"C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer","volume":"10","author":"Kucuksu","year":"2004","journal-title":"World J Gastroenterol"},{"key":"124","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.1232227","article-title":"Neutralizing tumor-promoting chronic inflammation: a magic bullet?","volume":"339","author":"Palucka","year":"2013","journal-title":"Science"},{"key":"125","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cell.2016.01.049","article-title":"The Basis of Oncoimmunology","volume":"164","author":"Coussens","year":"2016","journal-title":"Cell"},{"key":"126","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/cas.13330","article-title":"Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy","volume":"108","author":"Takahashi","year":"2017","journal-title":"Cancer Sci"},{"key":"127","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Blade","year":"2015","journal-title":"Am J Hematol"},{"key":"128","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"Mateos","year":"2014","journal-title":"Blood"},{"key":"129","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.bjc.6605872","article-title":"A phase I\/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer","volume":"103","author":"Berns","year":"2010","journal-title":"Br J Cancer"},{"key":"130","unstructured":"https:\/\/www.clinicaltrials.gov\/. 2016."},{"key":"131","first-page":"1","article-title":"Multicenter, open-Label, phase I\/II study of tocilizumab, an anti-Interleukin-6 receptor monoclonal antibody, combined with gemcitabine in patients with advanced pancreatic cancer","volume":"6","author":"Furuse","year":"2017","journal-title":"Journal of Medical Diagnostic Methods"},{"key":"132","first-page":"287","article-title":"Interleukin 6\/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer","volume":"7","author":"Kruger","year":"2010","journal-title":"Cancer Genomics Proteomics"},{"key":"133","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12885-017-3248-y","article-title":"Effects of omega-3 fatty acids on patients undergoing surgery for gastrointestinal malignancy: a systematic review and meta-analysis","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Cancer"},{"key":"134","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/hep.1840120517","article-title":"Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6","volume":"12","author":"Heinrich","year":"1990","journal-title":"Hepatology"},{"key":"135","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/MPA.0000000000000335","article-title":"Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels","volume":"44","author":"Ochiai","year":"2015","journal-title":"Pancreas"},{"key":"136","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia: therapeutic implications","volume":"8","author":"Carson","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"137","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2017.04.026","article-title":"Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status","volume":"81","author":"Tveit","year":"2017","journal-title":"Eur J Cancer"},{"key":"138","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s00520-016-3553-z","article-title":"A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients","volume":"25","author":"Cleeland","year":"2017","journal-title":"Support Care Cancer"},{"key":"139","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s10120-011-0039-z","article-title":"IL-6 serum levels predict postoperative morbidity in gastric cancer patients","volume":"14","author":"Kulig","year":"2011","journal-title":"Gastric Cancer"},{"key":"140","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s10620-009-0967-1","article-title":"Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection","volume":"55","author":"Jeong","year":"2010","journal-title":"Dig Dis Sci"},{"key":"141","first-page":"4201","article-title":"Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer","volume":"34","author":"Yoshimura","year":"2014","journal-title":"Anticancer Res"},{"key":"142","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12308","article-title":"Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients","volume":"177","author":"Pabinger","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"143","first-page":"373","article-title":"Parameters of biological activity in colorectal cancer","volume":"31","author":"Svacina","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T14:54:24Z","timestamp":1589036064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":143,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2018,7,3]]}},"alternative-id":["25661","30038723"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25661","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]}}}